GHRL and metabolic dysfunction-associated steatotic liver disease: In vivo, administration of ghrelin down-regulated endotoxin-induced pro-inflammatory cytokine release [35] and attenuated sepsis-induced acute lung injury [36], biliary obstruction-induced chronic hepatic injury [37], and non-alcoholic fatty liver disease (NAFLD)-induced liver injury and inflammation [38].